STAAR Surgical Company (STAA)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $1.32B
Last updated: Nov 17, 2026 at 4:10 PM ET
STAAR Surgical Company (STAA) Statistics
STAAR Surgical Company (STAA) has a market cap of $1.32B and an enterprise value of $1.19B. Revenue grew 42.36% over the last 12 months from the 12 months before. It holds $133.61M more cash than debt, 10.09% of its market cap.
Total Valuation
Enterprise value is 10.09% below the market cap, as cash exceeds debt.
| Market Cap | $1.32B |
|---|---|
| Enterprise Value | $1.19B |
| Latest price (Nov 17, 2026) | $25.56 |
Key Dates
| Last Earnings Date | Nov 4, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.9x and 3.4x. Its year-end P/E ranged from 30.0x to 220.1x from 2018 to 2023.
| P/E Ratio | 34.6x |
|---|---|
| Forward P/E | 89.1x |
| P/S Ratio | 3.9x |
| Forward P/S | 3.9x |
| P/B Ratio | 3.4x |
| P/TBV Ratio | 3.8x |
| P/FCF Ratio | 72.4x |
| P/OCF Ratio | 61.9x |
Enterprise Valuation
Counting debt and cash, the company is valued at 90.3x EBITDA and 64.9x free cash flow.
| EV / Sales | 3.6x |
|---|---|
| EV / EBITDA | 90.3x |
| EV / FCF | 64.9x |
Price Statistics
The stock is down 2.89% over 52 weeks and trades 10.89% above its 50-day average.
| Beta (1Y) | 0.39 |
|---|---|
| 52-Week Change | -2.89% |
| 1-Month Change | +16.82% |
| 3-Month Change | +3.65% |
| 6-Month Change | -21.60% |
| 5-Year Change | -79.28% |
| 10-Year Change | +190.41% |
| Total Return (1Y) | -2.89% |
| Total Return (3Y CAGR) | -9.80% |
| Total Return (5Y CAGR) | -25.53% |
| Return vs SPY (1Y) | -11.99% |
| Max Drawdown (1Y) | -42.77% |
| Max Drawdown (3Y) | -71.12% |
| Sharpe Ratio (1Y) | -0.01 |
| Correlation with SPY (1Y) | 0.10 |
| 50-Day Average | $23.05 |
| 200-Day Average | $23.97 |
| 52-Week Range | $15.59 to $35.87 |
| RSI (14 Days) | 55.4 |
| Average Volume (20 Days) | 775.84K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.68x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 4.68x |
|---|---|
| Quick Ratio | 4.08x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 0.14% over the last 12 months, against a 5-year average of -0.10%.
| Return on Equity (ROE) | 0.14% |
|---|---|
| Return on Assets (ROA) | 0.11% |
| ROE (5Y Average) | -0.10% |
| ROA (5Y Average) | 0.00% |
| ROIC (5Y Average) | -24.68% |
| Asset Turnover | 0.70x |
| Inventory Turnover | 1.89x |
| Receivables Turnover | 3.55x |
| Cash Conversion Cycle | 238 days |
Taxes
Income tax took 90.48% of pretax income over the last 12 months.
| Income Tax (TTM) | $5.04M |
|---|---|
| Effective Tax Rate | 90.48% |
Scores
STAA has an Altman Z-Score of 8.11, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 8.11 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $328.27M over the last 12 months.
| Revenue | $328.27M |
|---|---|
| Revenue Growth (YoY) | +42.36% |
| Gross Profit | $241.46M |
| Operating Income | $701.00K |
| Pretax Income | $5.57M |
| Net Income | $530.00K |
| EBITDA | $12.82M |
| Reported EPS (TTM) | $0.74 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 77.53% of the $485.16M in total assets.
| Cash and Equivalents | $133.61M |
|---|---|
| Total Debt | $0 |
| Net Cash | $133.61M |
| Net Cash Per Share | $2.64 |
| Working Capital | $277.89M |
| Shareholder Equity | $376.13M |
| Book Value Per Share | $7.44 |
| Tangible Book Value | $341.28M |
| Tangible Book Per Share | $6.75 |
| Total Assets | $485.16M |
| Total Liabilities | $109.03M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $3.55M of capital spending, operating cash flow left $17.85M of free cash flow.
| Operating Cash Flow | $21.40M |
|---|---|
| Capital Expenditures | $3.55M |
| Free Cash Flow | $17.85M |
| FCF Per Share | $0.36 |
| Depreciation and Amortization | $11.35M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 0.21%, against a 5-year average of -0.75%.
| Gross Margin | 73.56% |
|---|---|
| Operating Margin | 0.21% |
| Pretax Margin | 1.70% |
| Net Margin | 0.16% |
| EBITDA Margin | 3.91% |
| FCF Margin | 5.44% |
| Gross Margin (5Y Average) | 77.39% |
| Operating Margin (5Y Average) | -0.75% |
| Net Margin (5Y Average) | -1.51% |
Growth
Revenue fell 5.57% a year over 3 years.
| Revenue Growth (3Y CAGR) | -5.57% |
|---|---|
| Revenue Growth (5Y CAGR) | +7.93% |
| Book Value Per Share Growth (2Y CAGR) | -5.88% |
| Tangible Book Per Share Growth (2Y CAGR) | -10.22% |
Dividends and Yields
STAA does not pay a dividend. Its free cash flow yield is 1.38%.
| Earnings Yield | 2.89% |
|---|---|
| FCF Yield | 1.38% |
| Shareholder Yield | 0.00% |
Peer Position
Against 8 similar companies, STAA has the 4th highest P/E.
P/E RatioPeer median 24.2x
P/S RatioPeer median 3.0x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +9.06%
| P/E Ratio | 34.6x vs 24.2x median |
|---|---|
| P/S Ratio | 3.9x vs 3.0x median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +42.36% vs +9.06% median |
Analyst Forecast
Consensus estimates put revenue growth at 23.74% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +23.74% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About STAA
What is STAA's market cap?
STAAR Surgical Company has a market cap of $1.32B. Its enterprise value, which adds debt and subtracts cash, is $1.19B.
What is STAA's P/E ratio?
STAAR Surgical Company has a trailing P/E ratio of 34.6x and a forward P/E of 89.1x.
How many shares of STAA are outstanding?
STAAR Surgical Company has 50.54M shares outstanding. The count is up 1.83% from a year earlier.
Does STAA pay a dividend?
No. STAAR Surgical Company does not pay a dividend.
How much debt does STAA have?
STAAR Surgical Company has $0 of total debt and $133.61M of cash and equivalents, a net cash position of $133.61M.
STAA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts